We don't know for sure. The PR just states one die
Post# of 148169
"CytoDyn released safety data on its experimental drug for Covid-19 on Tuesday, but efficacy data were conspicuously absent, and the company disclosed that a patient had died following treatment with the therapy."
From the PR:
"Of the 84 patients treated, one patient died 33 days after enrollment due to an event unrelated to leronlimab."